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Abstract  
    This review work is done to show a significance of tubulin in cancer development. Within last decades there 
are a lot of studies have performed in this area. Now it is clear that there are an enormous number of functions in 
cell performing by microtubules, a structure unit of which is tubulin. Now it used widely as a predictive factor of 
tumor aggressiveness, but increasingly it becomes a target for studying and treatment elaboration, since it is well-
known that to nowadays tubulin-targeted medicines, such as taxanes or vinca-alkaloids, resistance develops 
rather quickly, so it consists a large problem in oncology. This work reveals basic microtubule functions, 
violations that it may undergo and consequences of these. Also it is described here the main modern tendencies in 
creation of remedy which will make it possible breakthrough treatment resistance barrier. 
 
Introduction 
    Cancer or malignant neoplasm is a genetic disorder 
that results from genetic or epigenetic alterations in 
the somatic cells. It’s well-known fact that cancer 
development is multistep process. Genetic and 
epigenetic changes are involved in alterations which 
ultimately lead to malignant transformation of the 
healthy cells [1]. 
 
    Modern direction of cancer treatment strive to 
targeted and personalized therapy, but unfortunately 
such expensive methods turn out low effective [2]. 
 
    This fact cause necessity to search different ways to 
resolve this problem not only by scientist but also 
pharmaceutical companies, which are interested the 
most to invest in really acting approaches and 
medicines.  
 
    Patients with stage III or IV diseases who are 
treated in clinics, often advance to metastatic stages 
and develop drug resistance and relapse involving 
lymph nodes, liver, lungs, bones, and brain resulting 
in systemic multiple organ failures (MOFs) [2]. 
 
    Especially interesting as have been noticed in a lot 
of analyses of tumors of diverse localizations that it 
very often correlates with high tubulin expression, 
more precisely its TUBB3 isotype. One of such 
investigations has proved that enhanced TUBB3 
expression is significantly associated with an 
advanced depth of tumor infiltration (p<0.003) and 
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the existence of lymph node metastases (p=0.023). 
The 5-year survival rate of the whole cohort in this 
survey was 35% and the median overall survival 2.15 
(95% CI=1.86-2.67) years. The TUBB3 protein high 
expressing patients demonstrated a significantly 
(p=0.0003) worse prognosis with 16% 5-year 
survival rate and a median overall survival of 1.27 
(95% CI=1.05-1.92) years compared to the low 
expressing patients (5 year survival 46%, median 
overall survival 3, 82 years). It was determined that 
high protein and mRNA expression levels of TUBB3 
(class III ß-tubulin) are associated with aggressive 
tumor features in esophageal adenocarcinomas [3]. 
Such results suggest that TUBB3 expression level can 
be reasonably accurate predictive factor. 
 
    Issues connected with tubulin consists a huge 
problem for all scientists and physicians which are 
looking for solutions to this problem. It is well-known 
that high-aggressive tumors initially often respond 
well to treatment, but later returns being far more 
aggressive than before, resulting in multiressitance 
and as consequence leads to death. It raises some of 
the main issues in oncology: which alterations lead to 
such aggressive behavior when relapse, and how can 
we counter this. 
 
    One solution came from studying of protein which 
 
Fig-1:  
    Tubulin Immunofluorescence - Changes in the quantity and quality of tubulin and the subspecies (cytoskeleton) in prostate 
cancer cells (LNCaP). On top: the cells were not stimulated by androgens. Bottom: The cells were stimulated by androgens for 
14 days. 
 
plays one of the main roles in cell behaviour – 
tubulin, which basically exists as microtubules 
structural unit. 
 
    Microtubules are cylindrical polymers composed of 
α- and β-tubulin subunits. These subunits associate 
longitudinally to form protofilaments and the 
protofilaments associate laterally to generate a 
microtubule [4]. 
 
    Microtubules are highly dynamic polymers as their 
ends can undergo rapid lengthening and shortening 
by the addition and removal of tubulin heterodimers, 
a phenomenon termed ‘dynamic instability’ [5]. 
 
    They are constantly lengthening and shortening 
throughout all phases of the cell cycle. During 
interphase, microtubules are nucleated at the 
centrosome (minus end) and radiate toward the cell 
periphery (plus end). Interphase microtubules are 
involved in the maintenance of cell shape and in the 
trafficking of proteins and organelles. Motor proteins 
translocate cell components on microtubule tracks, 
and protein–protein interactions with other adaptor 
proteins co-ordinate this process. Tubulin 
heterodimers also exist in soluble form in cells, and 
protein interactions with this tubulin population 
regulate microtubule behavior. The addition and 
removal of soluble tubulin heterodimers to dynamic 
microtubule ends is a highly regulated process [6].  
 
    During mitosis microtubules form the spindle to 
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enable correct chromosomal segregation. Tubulin-
binding agents (TBAs; e.g., taxanes, vinca alkaloids, 
epothilones, and eribulin) are important 
chemotherapeutic drugs that suppress spindle 
dynamics, causing subsequent mitotic arrest and cell 
death in rapidly dividing cells [7]. 
 
    In humans, microtubules are composed of 
combinations of nine a-tubulin isotypes and nine b-
tubulin isotypes, with the different tubulin isotypes 
possessing specific tissue and developmental 
distributions. The members of the tubulin family 
share a high degree of structural homology and are 
distinguished from one another by highly divergent 
sequences at their carboxy-terminal (C-terminal) tail 
[6]. 
 
Main Microtubules Functions Overview 
   Basic functions which microtubules perform in cell 
have become targets for investigating and further 
elaboration of medicines. So it is necessary to review 
shortly this one. 
 
Microtubule cytoskeleton in stress responses: 
   Microtubules influence homeostatic mechanisms 
and cell stress responses by regulating intracellular 
trafficking, acting as a scaffold for the co-localization 
and sequestration of stress response proteins, 
transmitting stress signals through cytoskeletal 
remodeling and modulating the induction of cell 
death pathways. Examples of their role in these 
processes are described below.  
 
Microtubules and cellular signaling: 
    While microtubules possess distinct functions in 
particular stress responses, the microtubule network 
also influences common signaling pathways engaged 
by a variety of cellular stresses. 
 
Microtubules and p53: 
    p53 is a key mediator of cellular stress responses 
and its activity heavily depends on microtubules. p53 
is translocated to the nucleus along microtubule 
tracks by dynein proteins in a complex with heat 
shock protein 90 (Hsp90) and Hsp90 immunophilins. 
 
Hypoxia: 
           In the absence of oxygen, HIF1a 
heterodimerizes to the constitutively active b subunit 
to initiate transcriptional changes.  
 
Oxidative stress: 
           Disturbed oxidative stress signaling has been 
determined as one of the widespread mechanism of 
cancer development. Tubulins interact with mediators 
of the oxidative stress response, with direct 
interactions between βIII-tubulin and glutathione S-
transferase µ  4 observed in ovarian cancer cells [6]. 
 
Metabolic stress: 
    The main reason why metabolic stress occurs in 
cancer cells is its uncontrolled division, resulting in 
disparity between nutrients needs and its supplying. 
Microtubules and tubulins are involved in responding 
to metabolic stress by sensing and modulating 
metabolic processes to maintain cellular energy levels. 
The microtubule network is hypothesized to play a 
critical role in the regulation of cellular metabolism 
[8]. 
 
Metabolic regulation: 
    Tubulins and microtubules have been suspected to 
function as a key modulator of mitochondrial 
metabolism for some time. Recent studies have 
demonstrated that tubulin is capable of interacting 
with, and blocking the VDAC, thereby regulating ATP 
and metabolite compartmentalization and 
contributing to the Warburg effect. 
 
Autophagy: 
    Macroautophagy (hereafter referred to as 
autophagy) can be induced in cells in response to 
diverse stresses, including metabolic and ER 
(endoplasmic reticulum) stress. Microtubules have 
been known to play a critical role in autophagic flux. 
 
Protein folding stress: 
    Misfolded proteins may arise from protein damage, 
inadequate chaperone activity, and malfunction of 
protein processing systems. Endoplasmic reticulum is 
highly important organelle for correct folding of 
membranous and secretory proteins, and it very 
depends on current cell condition, so such serious 
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changes as malignancy significantly disturb function 
of ER. 
     
Mitochondrial function: 
    As integrators of cell state and mediators of 
apoptotic signaling, mitochondria play a critical role in 
determining cell fate in response to stress. There is 
growing evidence that tubulin, microtubules, and the 
microtubule network regulate mitochondrial function 
in cancer. Microtubules exactly that structures which 
influence mitochondria trafficking and degradation, 
thereby sustaining its own stability and function on 
certain level. 
 
Cell death signaling: 
    It’s known that failure of cellular cell responses can 
result in cell death induction. Emerging evidence 
supports a role for tubulins and microtubules in the 
execution of cell death in response to stress. For 
instance,tubulins interact with regulators of 
mitochondrial membrane permeability and apoptosis 
[6]. 
 
Centrosomes and cell division: 
    Centrosomes are the major microtubule organizing 
centers (MTOC) of mammalian cells. Each centrosome 
consists of a pair of centrioles surrounded by 
pericentriolar material (PCM), from which spindle and 
astral microtubules emanate. In healthy cells, strict 
regulation of centrosome duplication ensures the 
formation of only two functional centrosomes, which 
assemble bipolar spindles to avoid chromosomal 
aberrations in mitosis. In contrast, many cancer cells 
harbor extra centrosomes accompanied by 
chromosomal instability. Thus, centrosome 
amplification and its structural aberrations is a 
hallmark of human cancers and have direct 
consequences on chromosomal instability and cancer 
cell invasion [1]. 
 
Tubulin and VDAC: 
    Last time there have been appeared a lot of reports 
about cytoskeleton dependence on bioenergetic 
function of cell. The main player in these models is the 
voltage-dependent anion channel (VDAC), located in 
the mitochondrial outer membrane. Most metabolites 
including respiratory substrates, ADP, and Pi enter 
mitochondria only VDAC. It’s has been established 
that passing of such high-energy substrates trough 
VDAC is regulated by β-tubulin, which bound to it. So 
it is presumed that such β-tubulin-VDAC interaction 
participates in regulation of cancer metabolism, being 
an important factor switching from oxidative 
phosphorylation, usually occurring in normal cells, to 
glycolysis, which is a distinctive feature of cancer cells 
[9]. 
 
     Microtubules are responsible for the mitochondrial 
subcellular arrangement and dynamics in skeletal and 
heart muscle cells. Their cytoarchitecture, isoform 
composition, interaction partners, and post-
translational modifications act as spatial cues to 
navigate mitochondria within the cellular space and 
help to stall and anchor mitochondria at sites of high 
energy demand [10]. 
 
Events that violate microtubules activity 
    The clinical observations are supported by 
numerous in vitro studies where altered βIII-tubulin 
levels confer resistance to a broad spectrum of drug 
classes in solid and hematological tumors [11]. 
 
    Growing evidences about significance of βIII-
tubulin in tumors development and aggressiveness 
suggest that it is one of the main survival factors in 
cancer; consequently it has become an object of close 
attention among cancer researchers [6]. So what 
should happen to microtubules, largely TUBB3 
isotype, it to show such altered behavior and high-
aggressive course of disease. There are at least nine 
isoforms of α-tubulin and nine isoforms of β-tubulin 
in humans [12]. 
 
Changes in tubulin composition: 
    Every tissue in human body has specific ratio of 
different tubulin isoforms, resulting in countless 
quantity of combinations. Features of its functioning 
are still poorly understood. But one for sure, that 
these specific combinations reflect qualities of 
metabolism in every particular tissue. Resulting from 
it we can conclude that changes in its number or ratio 
may be one of possible mechanisms of cancer 
progression.  
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    Altered tubulin isotype expression is the most 
widely characterized microtubule alteration 
reported in cancer and has been observed in both 
solid and hematological tumors. High βIII-tubulin 
level correlates with much poorer prognosis for 
patients with epithelial cancer. But it’s interesting 
that it associates not only with TBA resistance, but 
also βIII-tubulin influence sensitivity to non-tubulin 
targeted agents. The clinical observations are 
supported by numerous in vitro studies where 
altered βIII-tubulin levels confer resistance to a 
broad spectrum of drug classes in solid and 
hematological tumors [6]. 
 
    All these appeared proofs gave possibility to look 
another at tubulin role in cancer and features of 
treatment choosing depending on this factor [13]. 
 
Tubulin post-translational modifications: 
    As it is known microtubules are highly conserved 
structures and PTM is a good explanation of diverse 
functions carried by microtubules. Tubulins are 
subject to diverse post-translational modifications 
(PTMs). There are numerous of PTMs whose exact 
influence on tubulin remains poorly understood. 
Post-translational modifications are thought to 
regulate protein–protein interactions with the 
microtubule cytoskeleton, thereby affecting signaling 
events within the cell. The majority of these 
modifications is localized to the tubulin C-terminus 
and potentially imparts specific functions to the 
different tubulin isotypes. Microtubules and their 
role in cellular stress in cancer [6]. 
 
    For example acetylated tubulin is implicated in 
intracellular trafficking, endoplasmic reticulum (ER) 
localization, and ER–mitochondria interactions, as 
well as the regulation of microtubule dynamics [14]. 
 
    Removal of the final two residues of the βIVb-
tubulin C-terminal tail was identified in higher stage 
liver cancer and in a mouse model of hepatic 
carcinoma [15]. 
 
Microtubule-associated proteins: 
    A wide variety of proteins are known to interact 
with tubulins. One more factor which interacting 
with tubulin is responsible for it stability and 
treatment resistance is microtubule-associated 
proteins (MAPs). Aberrant expression of primarily 
neuronal MAPs (e.g., Tau, MAP2) has been detected in 
non-neuronal cancer tissue [6]. 
 
    For example it has been determined that one of 
such MAPs is tau, high level of which associates with 
poor prognosis in breast cancer and decreased 
sensitivity to taxane due to change of drug affinity to 
β-tubulin [16]. 
 
Tubulin localization in cell nuclei: 
    One study has established that βII-tubulin also is 
found in cell nuclei, moreover it can exist in non-
microtubule form and significantly impact on cell 
behavior. βII-tubulin may facilitate cancer growth and 
metastasis and, to accomplish this, may not need to 
be in microtubule form [17]. 
 
    Specific nuclear localization of βII-tubulin was 
demonstrated not only by immunohistochemistry 
using a monoclonal antibody to βII, but also by 
immunoblotting of a purified nuclear fraction, and by 
the fact that fluorescently labeled αβII-tubulin when 
micro-injected into these cells, went into the nuclei 
whereas fluorescently labeled, micro-injected αβIII 
and αβIV did not [18]. 
 
    It was found that over-expression of βII was 
correlated with a shorter life expectancy of patients 
with CRC. The life expectancy was even shorter for 
patients in whose tumors βII was localized to the cell 
nuclei [17]. 
 
Current directions in solution of tubulin 
questions: 
    Appearance of quiet detailed knowledge about 
tubulin and its functions within last decades led to 
elaboration of different ways to breakthrough this 
checkpoint in cancer study and create universal 
remedy, which provides to higher survivel rate of 
oncology patients with diverse localization of tumors. 
  
Inhibition of CPAP – tubulin interaction: 
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    CPAP – is a centrobin-centrosomal protein 
associated protein. Centrosome amplification is a 
distinctive trait of cancer which plays an important 
role in invasion. To survive, cancer cells cluster 
amplified extra centrosomes and achieve 
pseudobipolar division. It became a cause to elaborate 
ways to prevent clustering of extra centrosomes. 
Tubulin, by interacting with the centrosomal protein 
CPAP, negatively regulates CPAP-dependent peri-
centriolar material recruitment, and concurrently 
microtubule nucleation. Screening for compounds that 
perturb CPAP – tubulin interaction led to the 
identification of CCB02 (a selective inhibitor of CPAP–
tubulin interaction), which selectively binds at the 
CPAP binding site of tubulin. Genetic and chemical 
violation of CPAP – tubulin interaction causes extra 
centrosomes to nucleate enhanced numbers of 
microtubules prior to mitosis. This causes cells to 
undergo centrosome declustering, prolonged 
multipolar mitosis, and cell death. Assay in which was 
researched CCB02 reveals high anti-invasive activity 
in different cancer types, in particular in tyrosine 
kinase inhibitor (TKI)-resistant EGFR-mutant non-
small-cell lung cancers. So, it is a perspective direction 
to use centrosome quantity as marker to develop 
global new treatment approach, especially those which 
exhibit high incidence of centrosome amplification [1]. 
 
βIII/βIV-tubulin inhibitor (VERU-111) is new 
developing remedy for pancreatic cancer: 
    Recent studies have reported major roles of β III 
and β IV-tubulins in pancreatic cancer as these 
isotypes are highly expressed in pancreatic tumors, 
while absent in normal pancreas (acinar and 
pancreatic islets) [19]. 
 
    The expression of these tubulins has been 
associated with pancreatic cancer progression, 
metastasis and chemoresistance. Additionally, β III-
tubulin knockdown reduced the pancreatic tumor 
growth and metastasis in an orthotropic xenograft 
mouse model. A novel synthetic molecule that is 
known to overcome multidrug resistance 
preferentially inhibits the expression of β III and β IV-
tubulins via restoring the expression of miR-200c in 
PanCa cells. Also it was demostrated that VERU-111 
effectively inhibits growth and metastatic phenotypes 
of pancreatic cancer cells in in vitro and in vivo model 
systems [20]. 
 
Developments of Chinese researchers – 
Antiproliferative aspidosperma-type 
monoterpenoid indole alkaloids from bousigonia 
mekongensis: 
    Innate and acquired drug resistance, especially 
multidrug resistance (MDR), are major obstacles in 
cancer chemotherapy. In this survey was determined 
that high level of P-glycoprotein correlates with poor 
prognosis, at the same time the most antimicrotubule 
drugs such as paclitaxel or vincristine are it 
substrates. Recent study established that there is 
another, the colchicine site (CS) on the α/βtubulin 
dimer, antimitotic agents to which turned out highly 
effective in cells with βIII-tubulin overexpression. So, 
a new approach to treatment with antitubulin agents 
has appeared, and what is important it can 
breakthrough resistance to general used antitubulin 
drugs targeted to P -gp. 
 
    In order to find such colchicine site substrates 
investigators sought among monoterpenoid indole 
alkaloids which are structurally diverse natural 
products found in plants of the family Apocynaceae. 
Among them, vincristine and its derivatives are well 
known for their antiproliferative activity. Among 
them, vincristine and its derivatives are well known 
for their anticancer activity. There are a lot of 
different monoterpoid indole alkaloids in this species. 
To be more precise there are fourteen alkaloids, 
which were isolated and investigated, consequently 
got numbers from 1 to 14. It was determined that 
alkaloids 3, 6, 9, 13 have similar spectra of action and 
turned out effective even in multi-resistant subline 
cells. The mechanism is in cell cycle arrest at the 
G2/M phase by inhibiting tubulin polymerization as 
well as mitotic bipolar spindle formation. This 
analysis also suggested that a 14, 15-double bond or 
3α-acetonyl group is critical for enhanced 
antiproliferative activity [21]. 
 
Investigation of benefit from tubulin-targeted 
and immune therapeutics 
    Immune therapy of cancer recently has become 
 Manuscript no: 2582-0370-2-15 Volume: 2      Issue: 2  21 
Asp Biomed Clin Case Rep 
 
Review Article 
Citation: Dolhyi V, Avierin D, Hojouj M, Bondarenko I. Tubulin Role in Cancer Development and Treatment. Asp 
Biomed Clin Case Rep. 2019 Sept 5;2(2):15-22. 
 
very promising direction of treatment of many cancer 
types. Appeared results that tubulin is close connected 
with immune response has increased interest of 
combining immune and tubulin-targeted drugs. There 
are two main processes occurring among 
microtubules – polymerization and depolymerization. 
So, antitubulin drugs also divide into two groups: anti-
depolymerization agents such as the taxane family, 
and anti-polymerization agents such as colchicine and 
vinka alkaloids. They interact with immune system in 
different ways even within the same class. It was 
determined that certain antipolymerization agents 
such as colchicine appear to depress most immune cell 
types, while inducing dendritic cell maturation and 
increasing M1 macrophage population. In contrast, the 
vinblastine anti-polymerization agent activates many 
of these cell types, although downregulating Treg 
cells. The combination of tubulin-targeting anticancer 
agents and immune therapy appears to be especially 
promising, as several lines of evidence suggest that 
agents functioning as anti-polymerization and anti-
depolymerization of microtubules can enhance the 
body’s immune response. The next logical step would 
be a better understanding of the molecular mechanism 
about how different tubulin-targeting agents can 
enhance different immunotherapeutic agents in 
various tumor environments. Undoubtedly, this 
knowledge will eventually bring about highly effective 
cancer therapies in individual patients [22]. 
 
Conclusion 
    To summarize shortly it is necessary to say that 
quite probably the role of tubulin as treatment target 
will increase constantly. It is related to quite scanty 
knowledge we have at this time. Of course, a great 
work has done to know about tubulin, but I think it 
almost nothing, because there are a large number of 
comprehensive interactions between numerous 
cellular structures and cascades. So it is a great 
incentive to move on. 
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